Ratings Insecticides (India) Limited

Equities

Market Closed - Bombay S.E. Other stock markets 06:00:50 2024-05-06 am EDT			5-day change	1st Jan Change
574.8 ^INR	-0.71%		-0.40%	-15.06%

Mar. 26	Insecticides Limited Announces Reconstitution of Committees	CI
Feb. 06	Transcript : Insecticides Limited, Q3 2024 Earnings Call, Feb 06, 2024

The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.

The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
The valuation of the company is particularly high given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
INSECTICIDES (INDIA) LIMITED	-15.06%	205M		-
JIANGSU YANGNONG CHEMICAL CO., LTD.	+4.93%	3.62B		C-
SHANDONG WEIFANG RAINBOW CHEMICAL CO., LTD	-13.64%	2.23B		C+
ANHUI GUANGXIN AGROCHEMICAL CO., LTD.	+7.03%	1.86B		-
ZHEJIANG XINAN CHEMICAL INDUSTRIAL GROUP CO.,LTD	+1.86%	1.67B		-
NUFARM LIMITED	-0.57%	1.3B		B
SHENZHEN NOPOSION CROP SCIENCE CO., LTD.	+10.90%	1.23B		-
LIER CHEMICAL CO.,LTD.	-16.54%	1.06B		-
NANTONG JIANGSHAN AGROCHEMICAL & CHEMICALS CO.,LTD.	+0.29%	997M		-
BSM CHEMICAL CO.,LTD.	+3.79%	839M	-	-

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality